MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.

EP: 1.Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP: 2.Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP: 3.Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

Now Viewing

EP: 4.MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

1. Dr Ajai Chari to Dr Raje: What are your thoughts on minimal residual disease negativity as a primary outcome?
2. Dr Ajai Chari to Dr Rossi: For patients who are eligible for transplantation but decline, what is your treatment approach for this patient population? Do you have a preferred induction regimen?

Related Videos